Mer­ck, Pfiz­er make their PhI­II case for an SGLT2 late­com­er to the block­buster show­down in di­a­betes

What do you do when you’re the last to ar­rive at the SGLT2 par­ty, long af­ter it got start­ed? You start lin­ing up da­ta that start to dif­fer­en­ti­ate your Type 2 di­a­betes drug, at least some­what.

That’s what Mer­ck and Pfiz­er were aim­ing for over the week­end when their in­ves­ti­ga­tors of­fered up sol­id da­ta from two new Phase III tri­als of er­tugliflozin.

Pegged by an­a­lysts for a like­ly FDA ap­proval by the end of this year (there’s a De­cem­ber PDU­FA date on three NDAs for the drug and these two com­bos), the re­searchers tout­ed re­sults that demon­strat­ed the drug’s abil­i­ty to ef­fec­tive­ly cut A1C when com­bined with ei­ther Mer­ck’s DPP-4 drug Janu­via or the main­stay met­formin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER